Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Lonza to sell finished dosage plants to NextPharma

by Rick Mullin
January 23, 2021 | A version of this story appeared in Volume 99, Issue 3

 

Lonza will sell two plants that make liquid-filled hard capsules and softgel finished drugs to NextPharma, a drug services firm specializing in these areas. The plants in France and Scotland employ about 260 and 130 people, respectively. Lonza, which took on the operations when it bought Capsugel in 2016, intends to largely exit liquid-filled capsules and softgels for pharmaceuticals. It recently said it would invest about $96 million to expand its unfilled-capsule production by 30 billion per year.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.